European vaccine strains of the porcine reproductive and respiratory syndrome virus

• US 5,925,359 A
• Filed: 10/09/1997
• Issued: 07/20/1999
• Est. Priority Date: 10/09/1996
• Status: Expired due to Term

• Current Assignee: Intervet International BV (Merck & Co., Inc.)
• Original Assignee: Akzo Nobel N.V. (Nouryon BV)
• Inventors: Demaret, Jean Guillaume Joseph, Van Woensel, Petrus Alphonsus Maria
• Primary Examiner(s): Smith, Lynette F.
• Application Number:
  US08/947,696
• Time in Patent Office: 649 Days
• Field of Search: 424/204.1, 424/218.1, 424/209.1, 424/815, 435/235.1, 435/236, 435/237, 435/238, 435/239, 530/350
• US Class Current: 424/204.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: Y10S 424/815 Viral vaccine for porcine species, e.g. swine

Abstract

The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, having as a unique feature that they are non-infectious to macrophages, and to methods for the production of such strains. The invention also provides vaccines for the protection of pigs against PRRS, based on these strains, as well as methods for the production of such vaccines.

Claims

1. A live attenuated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) of a European serotype, which is not infectious to macrophages.

2. The live attenuated PRRSV according to claim 1, which is reactive with monoclonal antibody A27 as produced by hybridoma A27 deposited with the Collection Nationale de Cultures de Micro-organismes (CNCM) of the Institut Pasteur at Paris France under No. I-1401, but not with monoclonal antibody A35 as produced by hybridoma A35 deposited with the CNCM of the Institut Pasteur at Paris France under No. I-1402.

3. The live attenuated PRRSV according to claim 2, which is of the strain as deposited at the Institut Pasteur under Accession Number I-1758.

4. A method for the preparation of the live attenuated PRRSV according to claim 1, comprising adapting an MA 104-grown PRRSV of a European serotype to non-MA 104 mammalian cells.

5. The method according to claim 4, wherein non-MA104 primate cells are used as the non-MA104 mammalian cells.

6. The method according to claim 5, wherein Vero cells are used as the non-MA104 primate cells.

7. A vaccine for the protection of pigs against PRRSV infection, comprising the live attenuated PRRSV according to claim 1 and a pharmaceutically acceptable carrier.

8. The vaccine according to claim 7, which further comprises one or more non-PRRSV attenuated or inactivated pathogens or antigenic material thereof.

9. The vaccine according to claim 8, wherein said non-PRRSV pathogens are selected from Pseudorabies virus, Porcine influenza virus, Porcine parvovirus, Transmissible gastroenteritis virus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

10. The vaccine according to claim 7, which comprises a carrier that is suitable for intradermal or intramuscular application.

11. The vaccine according to claim 7, which is in freeze-dried form.

12. A method for the preparation of a live attenuated vaccine for combating PRRS, comprising admixing a live attenuated PRRSV according to claim 1 with a pharmaceutically acceptable carrier.

13. The method according to claim 12, wherein the live attenuated PRRSV deposited at the Institut Pasteur under Accession Number I-1758 is used for admixing.

14. A vaccine for the protection of pigs against PRRSV infection, comprising the PRRSV according to claim 2 and a pharmaceutically acceptable carrier.

15. A vaccine for the protection of pigs against PRRSV infection, comprising the PRRSV according to claim 3 and a pharmaceutically acceptable carrier.

16. The vaccine according to claim 14, which further comprises one or more non-PRRSV attenuated or inactivated pathogens or antigenic material thereof.

17. The vaccine according to claim 16, wherein said non-PRRSV pathogens are selected from Pseudorabies virus, Porcine influenza virus, Porcine parvovirus, Transmissible gastroenteritis virus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

18. The vaccine according to claim 15, which further comprises one or more non-PRRSV attenuated or inactivated pathogens or antigenic material thereof.

19. The vaccine according to claim 18, wherein said non-PRRSV pathogens are selected from Pseudorabies virus, Porcine influenza virus, Porcine parvovirus, Transmissible gastroenteritis virus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.